IQVIA Holdings Inc

IQVIA Holdings Inc

IQV

Get informed when a big investor buys or sells

+ Follow
Market Cap$30.41B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
IQVIA Holdings IncIQVIA Holdings Inc22.2-22%1.90.7

Earnings Call Q1 2026

May 5, 2026 - AI Summary

Strong results + guidance beat (good surprise): - Q1 2026 revenue: $4.151B, +8.4% YoY reported (+6% at constant currency) and exceeded the high end of guidance. - Adjusted diluted EPS: $2.90, +7.4% YoY, also above the high end of guidance. - Adjusted EBITDA: $932M, +5.5% YoY. - Commercial & R&D acceleration: Organic growth accelerated strongly, with Commercial Solutions organic growth ~5% (reported +11.6%) and R&D Solutions organic growth ~3% (reported +6.2%).
Commercial Solutions momentum (opportunity): - Key strength areas: Patient Solutions (Real World in Commercial) with strong double-digit growth, plus Analytics & Consulting showing the highest growth in three years. - Management attributes growth to AI-enabled “agentification” and innovation that helps clients manage complex data, accelerate decisions, and modernize workflows. - Pipeline/premise: Management said demand/pipeline hit record levels, suggesting continued ramp in client spend and service adoption.
R&D bookings nuance: book-to-bill looks “low” but profitability impact is expected to be minimal (bad headline clarified + surprising driver): - Backlog: reached a record $34.2B at quarter end; $8.9B of backlog expected to convert to revenue in the next 12 months (nearly 8% YoY growth on a recast basis). - Book-to-bill was 1.04 despite solid service-fee bookings because pass-through bookings were unusually low (about one-third below historic average), driven by trial mix (more full-service trials with lower pass-throughs). - Key investor takeaway: Management emphasized pass-throughs don’t affect margin (zero profitability drop-through). They also highlighted their bookings are conservative (book only when contracted), which can distort quarterly book-to-bill and make it a poor growth predictor.

Exclusive for Stockcircle Pro members

Sign upSign Up
$225.50

Target Price by Analysts

23.9% upsideIQVIA Holdings Target Price DetailsTarget Price
$256.83

Current Fair Value

41.1% upside

Undervalued by 41.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$30.41 Billion
Enterprise Value$32.97 Billion
Dividend Yield$- (-)
Earnings per Share$7.91
Beta1.18
Outstanding Shares168,400,000

Return

Return on Equity22.26%ROE
Return on Assets4.67%
Return on Invested Capital10.99%

Valuation & Multiples

P/E Ratio22.15P/E Ratio
PEG220.66PEG
Price to Sales1.86Price to Sales
Price to Book Ratio4.92Price to Book Ratio
Enterprise Value to Revenue1.98
Enterprise Value to EBIT14.06
Enterprise Value to Net Income23
Total Debt to Enterprise0.14
Debt to Equity0.72Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 6, 2026
EPS Estimate
$2.83
Average shareholder expectation
Revenue Estimate
$4.10 B
Average shareholder expectation

Next Earnings Call

Expected Date
July 28, 2026
EPS Estimate
$3.03
Average shareholder expectation
Revenue Estimate
$4.31 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.9910▲ 7.02%
Total Calls845,600▼ 26.53%
Total Puts837,991▼ 20.93%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %91.70%▼ 2.83%
Total Invested$26.71B▼ 26.35%
Investors Holding1,093▼ 65.00%

ESG Score

No data

About IQVIA Holdings Inc

CEO: Ari Bousbib

Relevant Senate Committees

Joint Committee on Taxation

This committee provides the technical analysis and revenue estimates for all tax legislation, directly influencing corporate tax policy that impacts IQVIA's profitability, capital investment, and overall financial health.

Finance

This committee's control over taxation, trade, and entitlement spending (like Medicare) directly impacts corporate profitability, healthcare sector funding, and drug pricing, all of which critically affect IQVIA's clients and, by extension, its business model.

Appropriations

This committee directly allocates federal spending, and its subcommittees can determine funding for health programs, scientific research, and healthcare-related initiatives that IQVIA or its clients may participate in or benefit from.

Health, Education, Labor, and Pensions

This committee directly regulates the FDA and NIH, which are central to the drug approval process and research funding, both core to IQVIA's clinical research and life sciences services. Labor laws also impact its workforce.